Can epigenetic biomarkers lead us to precision medicine in predicting treatment response and remission for patients being considered for ECT?

Tami Feng, Nagy A. Youssef

Research output: Contribution to journalArticle


While electroconvulsive therapy (ECT) is the gold standard for the treatment of depression, there is currently a lack of clinically useful biomarkers predictive of treatment response. Epigenetics provides reasonable potential as a biomarker for treatment response for ECT, given that the study of epigenetics combines both the impact of biology and environment in the shaping of psychopathology. Initial limited studies are promising. Further studies to establish precision medicine in term of ECT treatment response using epigenetics predictors can provide great benefit to both patients and physicians in saving time, money, and frustration.

Original languageEnglish (US)
Article number112659
JournalPsychiatry Research
Publication statusPublished - Feb 2020



  • Depression
  • ECT
  • Electroconvulsive therapy
  • Epigenetic
  • Genomics
  • Personalized medicine
  • Precision medicine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this